[
    [
        {
            "time": "2022-11-28",
            "original_text": "医药行业周报：OMICRON成热议 CDMO和上游边际改善",
            "features": {
                "keywords": [
                    "OMICRON",
                    "CDMO",
                    "上游",
                    "边际改善"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：OMICRON成热议 CDMO和上游边际改善",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-11-29",
            "original_text": "南财脱水研报丨奥密克戎对医疗板块影响如何，复盘德尔塔或能参考",
            "features": {
                "keywords": [
                    "奥密克戎",
                    "医疗板块",
                    "德尔塔",
                    "复盘"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "南财脱水研报丨奥密克戎对医疗板块影响如何，复盘德尔塔或能参考",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-11-30",
            "original_text": "海外机构调研股名单 智飞生物最受关注",
            "features": {
                "keywords": [
                    "智飞生物",
                    "海外机构",
                    "调研"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "海外机构调研股名单 智飞生物最受关注",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-12-01",
            "original_text": "盛通股份：公司已与国内获批上市的中国生物、智飞生物等新冠疫苗生产企业合作，订单量充盈",
            "features": {
                "keywords": [
                    "盛通股份",
                    "中国生物",
                    "智飞生物",
                    "新冠疫苗",
                    "订单量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "盛通股份：公司已与国内获批上市的中国生物、智飞生物等新冠疫苗生产企业合作，订单量充盈",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-12-02",
            "original_text": "变异毒株来势汹汹！高回撤绩优热门股名单来了",
            "features": {
                "keywords": [
                    "变异毒株",
                    "高回撤",
                    "绩优",
                    "热门股"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "变异毒株来势汹汹！高回撤绩优热门股名单来了",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2022-12-03",
            "original_text": "医药生物行业2022年投资策略报告：返璞归真 迎接高质量发展",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "高质量发展"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业2022年投资策略报告：返璞归真 迎接高质量发展",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2022-12-04",
            "original_text": "生物医药行业周报：加强新时代老龄工作的意见发布 康复行业或将受益",
            "features": {
                "keywords": [
                    "生物医药",
                    "老龄工作",
                    "康复行业",
                    "意见发布"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "生物医药行业周报：加强新时代老龄工作的意见发布 康复行业或将受益",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-12-05",
            "original_text": "智飞生物：公司现有预防新冠产品智克威得临床试验数据显示有很好的安全性和防病效果",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠",
                    "智克威得",
                    "安全性",
                    "防病效果"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：公司现有预防新冠产品智克威得临床试验数据显示有很好的安全性和防病效果",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-12-06",
            "original_text": "智飞生物：正积极推进重组新冠疫苗的后续认证工作",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新冠疫苗",
                    "认证工作"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：正积极推进重组新冠疫苗的后续认证工作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-12-07",
            "original_text": "智飞生物：mRNA技术在疫苗开发、肿瘤治疗等方面有优势",
            "features": {
                "keywords": [
                    "智飞生物",
                    "mRNA技术",
                    "疫苗开发",
                    "肿瘤治疗"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：mRNA技术在疫苗开发、肿瘤治疗等方面有优势",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-12-08",
            "original_text": "医药板块反弹强烈，硕世生物涨超15%",
            "features": {
                "keywords": [
                    "医药板块",
                    "反弹",
                    "硕世生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药板块反弹强烈，硕世生物涨超15%",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-12-09",
            "original_text": "超级病毒全球刷屏，投资逻辑彻底变了？一类股危险了",
            "features": {
                "keywords": [
                    "超级病毒",
                    "投资逻辑",
                    "一类股"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "超级病毒全球刷屏，投资逻辑彻底变了？一类股危险了",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        }
    ]
]